TP53 mutational status may be a predictive biomarker of response to vascular endothelial growth factor receptor (VEGFR) inhibition with pazopanib in patients with advanced sarcoma, a new study published online ahead of print in the Annals of Oncology has shown.1

For the study, researchers sought to investigate whether TP53 DNA mutational status impacts progression-free survival in patients with advanced sarcomas treated with pazopanib. Pazopanib is a potent and selective multikinase inhibitor that blocks tumor growth and inhibits angiogenesis and is approved by the U.S. Food and Drug Administration for the treatment of advanced soft tissue sarcomas and advanced/metastatic renal cell carcinoma.

Researchers retrospectively analyzed data from 19 patients with advanced sarcoma who received treatment with pazopanib at the Ohio State James Comprehensive Cancer Center. Both TP53 and mutation observed in at least 20% of patients, including Rb1, were evaluated for a correlation with progression-free survival.

RELATED: Survivors of Osteosarcoma Face Risk of Neurocognitive Impairment

Results showed that only TP53 was predictive of progression-free survival in patients treated with pazopanib. Researchers found that median progression-free survival was 208 days in patients with TP53 mutations compared with 136 days in those with TP53 wild-type tumors (HR, 0.38; 95% CI, 0.09 – 0.83; P = .036).

“Larger, prospective studies are necessary to confirm these findings,” the authors concluded.

Reference

  1. Koehler K, Liebner D, Chen JL. TP53 mutational status is predictive of pazopanib response in advanced sarcomas [published online ahead of print on December 8, 2015]. Ann Oncol. doi: 10.1093/annonc/mdv598.